Burzynski Research Institute (BZYR) Total Liabilities (2011 - 2025)
Burzynski Research Institute (BZYR) posted Total Liabilities of $69608.0 for Q4 2025, down 1.83% sequentially from $70902.0 in Q3 2025, and up 215.84% YoY from $22039.0 in Q4 2024.
Burzynski Research Institute (BZYR) Total Liabilities (2011 - 2025) Analysis & Trends
Burzynski Research Institute has reported Total Liabilities for 15 years, with the latest figure at $69608.0 in Q4 2025.
- Quarterly Total Liabilities rose 215.84% year-over-year to $69608.0 in Q4 2025, while the trailing twelve-month figure through Nov 2025 was $69608.0 (up 215.84% YoY) and the FY2025 annual result came in at $42484.0, up 54.86% from the prior year.
- Total Liabilities declined to $69608.0 in Q4 2025 per BZYR's latest filing, from $70902.0 in the prior quarter.
- Over five years, Total Liabilities peaked at $128865.0 in Q2 2024 and troughed at $1389.0 in Q4 2021.
- A 5-year average of $44169.6 and a median of $39165.5 in 2023 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2021 and 2022: Total Liabilities plunged 98.94% in 2021, then jumped 1946.08% in 2022.
- Over 5 years, Total Liabilities stood at $1389.0 in 2021, then surged by 1946.08% to $28420.0 in 2022, then grew by 26.13% to $35847.0 in 2023, then slumped by 38.52% to $22039.0 in 2024, then surged by 215.84% to $69608.0 in 2025.
- According to Business Quant data, Total Liabilities over the past three periods registered $69608.0, $70902.0, and $71237.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Burzynski Research Institute | 1.31 Mn | 1.31 Mn | - | 69,608.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | 69,608.00 |
| Aug 31, 2025 | 70,902.00 |
| May 31, 2025 | 71,237.00 |
| Feb 28, 2025 | 42,484.00 |
| Nov 30, 2024 | 22,039.00 |
| Aug 31, 2024 | 89,250.00 |
| May 31, 2024 | 128,865.00 |
| Feb 29, 2024 | 27,433.00 |
| Nov 30, 2023 | 35,847.00 |
| Aug 31, 2023 | 6,273.00 |
| May 31, 2023 | 71,366.00 |
| Feb 28, 2023 | 15,661.00 |
| Nov 30, 2022 | 28,420.00 |
| Aug 31, 2022 | 15,304.00 |
| May 31, 2022 | 44,146.00 |
| Feb 28, 2022 | 3,455.00 |
| Nov 30, 2021 | 1,389.00 |
| Aug 31, 2021 | 29,671.00 |
| May 31, 2021 | 63,242.00 |
| Feb 28, 2021 | 46,799.00 |